Red blood cell exchange for sickle cell disease
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study looks at whether regular red blood cell exchange (a treatment that replaces sickled red blood cells with healthy ones) can reduce blood clotting and inflammation in people with sickle cell disease. It aims to see if this treatment helps protect your blood vessels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have sickle cell disease type SS or S/beta thalassemia.
- You have been having red blood cell exchange treatments for more than 3 months.
- You are covered by health insurance (social security) in France.
- You can understand the study's purpose and are willing to participate.
- You have read the study information and agree to take part.
- You are not currently taking anti-inflammatory or anti-clotting medications (like NSAIDs or antiplatelet drugs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether a “half-matched” donor bone marrow transplant, with special medicines to calm the immune system before transplant, can improve outcomes for people with sickle cell disease. It may help high-risk patients who have frequent complications and don’t have a fully matched donor.
This trial tests CS-206, an experimental therapy for people with sickle cell disease. It aims to reduce severe complications like pain crises, acute chest syndrome, strokes, and other serious events. You may qualify if you have a specific genetic type of sickle cell disease and have experienced complications despite standard treatments.
This trial tests a drug that helps your body release stem cells so they can be collected for a future bone marrow transplant. It may help make the transplant process safer and more effective for people with sickle cell disease.
This trial tests a new gene therapy that may help people with severe sickle cell disease by editing their own blood stem cells to produce healthy red blood cells. It aims to reduce painful crises and other complications.
This trial tests a stem cell transplant from a half-matched donor using a strong conditioning regimen and a drug called defibrotide to protect organs. It aims to cure sickle cell disease in patients who have had serious complications like stroke, chest syndrome, or frequent pain episodes.
This study tests whether giving regular blood transfusions during early pregnancy can help prevent complications for women with sickle cell disease. If you are between 6 and 20 weeks pregnant, you may join to see if this treatment improves outcomes.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.